Patients in the European Union ( @ patients ) and the United States ( @ patients ) were randomly assigned , in a @:@ ratio , to receive a subcutaneous implant containing either afamelanotide or placebo every @ days ( a total of five implants in the European Union study and three in the U.S study ) .